Search Results

Your search matched 9 results


Why the New CMS Oncology Model is an Inflection Point in Advancing Health Equity | Blog

On July 1st, The Centers for Medicare & Medicaid Services, through its Center for Medicare & Medicaid Innovation (CMMI), announced its newest voluntary oncology payment model, Enhancing Oncology Model (EOM).


ICER’s Final Evidence Report on bluebird bio’s Gene Therapy, beti-cel, Highlights Alternative Payment Model for One-Time Curative Treatment | Blog

In July, the Institute for Clinical and Economic Review (ICER) published its final evidence report for bluebird bio’s Zynteglo (betibeglogene autotemcel or “beti-cel”) for the treatment of beta thalassemia, a rare, debilitating blood disorder.


Biosimilar Elimination Red Tape Act | Blog

In November 2022, Sen.


State-Level Drug Pricing Policy Accelerating: Life Sciences Companies Can Contextualize Value & Access to Policymakers | Blog

While federal drug pricing reform in the Build Back Better Act (BBBA) is stalled at the Senate, states are taking the issue into their own hands.


January Drug Price Increases Fuel Continued Scrutiny; Underscores Need to Communicate Pricing Factors | Blog

With a global pandemic, rising inflation, and continued political pressures, drug pricing will undoubtedly remain a big focus in 2022.


What the lecanemab Approval Means for the Life Science Industry | Blog

The Food and Drug Administration (FDA) approved Alzheimer’s disease (AD) drug lecanemab through its accelerated approval program.


What the CMS National Coverage Decision Means for the Life Science Industry   | Blog

What the CMS National Coverage Decision Means for the Life Science Industry  


ICER Policy Proposals for Orphan Drug Pricing | Blog

The Institute for Clinical and Economic Review (ICER) recently published the white paper “The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability.”


Health Equity, Real-World Evidence: A Trend to Watch | Blog

The Biden administration cited health equity as one of its top 5 health priorities in a Health Affairs blog.